[1]
|
孙菲菲, 吉挺. 低分子肝素抗凝在连续肾脏替代治疗中的应用效果[J]. 护理研究, 2022, 36(17): 3116-3120.
|
[2]
|
Roe, N.A., Wiss, A.L., Volgas, S., et al. (2022) Review of Anticoagulation in Continuous Renal Re-placement Therapy. Critical Care Nursing Quarterly, 45, 144-155. https://doi.org/10.1097/CNQ.0000000000000397
|
[3]
|
Shindo, M., Ookawara, S., Kitano, T., et al. (2019) Sus-tained Severe Intestinal Edema after Nafamostat Mesilate-Associated Anaphylactic Reaction During Hemodialysis. Ne-frología (English Edition), 39, 202-204.
https://doi.org/10.1016/j.nefroe.2019.02.005
|
[4]
|
Legrand, M. and Tolwani, A. (2021) Anticoagulation Strategies in Continuous Renal Replacement Therapy. Seminars in Dialysis, 34, 416-422. https://doi.org/10.1111/sdi.12959
|
[5]
|
Zhou, Y., Wu, J., Xue, G., et al. (2022) Structural Study of the uPA-Nafamostat Complex Reveals a Covalent Inhibitory Mechanism of Nafamostat. Biophysical Journal, 121, 3940-3949. https://doi.org/10.1016/j.bpj.2022.08.034
|
[6]
|
Lang, Y., Zheng, Y., Qi, B., et al. (2022) Anticoagula-tion with Nafamostat Mesilate During Extracorporeal Life Support. International Journal of Cardiology, 366, 71-79. https://doi.org/10.1016/j.ijcard.2022.07.022
|
[7]
|
Tandukar, S. and Palevsky, P.M. (2019) Continuous Renal Re-placement Therapy: Who, When, Why, and How. CHEST, 155, 626-638. https://doi.org/10.1016/j.chest.2018.09.004
|
[8]
|
Minakata, D., Fujiwara, S.-I., Ikeda, T., et al. (2019) Comparison of Gabexate Mesilate and Nafamostat Mesilate for Disseminated Intravascular Coagulation Associated with Hematologi-cal Malignancies. International Journal of Hematology, 109, 141-146. https://doi.org/10.1007/s12185-018-02567-w
|
[9]
|
Hirayama, T., Nosaka, N., Okawa, Y., et al. (2017) AN69ST Membranes Adsorb Nafamostat Mesylate and Affect the Management of Anticoagulant Therapy: A Retrospective Study. Journal of Intensive Care, 5, Article No. 46.
https://doi.org/10.1186/s40560-017-0244-x
|
[10]
|
Arimura, T., Abe, M., Shiga, H., et al. (2017) Clinical Study of Blood Purification Therapy in Critical Care in Japan: Results from the Survey Research of the Japan Society for Blood Purification in Critical Care in 2013. Journal of Artificial Organs, 20, 244-251. https://doi.org/10.1007/s10047-017-0968-3
|
[11]
|
Murdeshwar, H.N. and Anjum, F. (2022) Hemodialysis. StatPearls Publishing, Treasure Island.
|
[12]
|
Zarbock, A., Kullmar, M., Kindgen-Milles, D., et al. (2020) Effect of Re-gional Citrate Anticoagulation vs Systemic Heparin Anticoagulation during Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients with Acute Kidney Injury: A Randomized Clinical Trial. JAMA, 324, 1629-1639.
https://doi.org/10.1001/jama.2020.18618
|
[13]
|
Singh, S. (2020) Anticoagulation during Renal Replacement Therapy. Indian Journal of Critical Care Medicine, 24, S112-S116. https://doi.org/10.5005/jp-journals-10071-23412
|
[14]
|
Lee, Y.K., Lee, H.W., Choi, K.H. and Kim, B.S. (2014) Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study. PLOS ONE, 9, e108737. https://doi.org/10.1371/journal.pone.0108737
|
[15]
|
Kidney Disease: Improving Global Outcomes (KDIGO) Glo-merular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Dis-eases. Kidney International, 100, S1-S276.
https://doi.org/10.1016/j.kint.2021.05.021
|
[16]
|
Zhang, W., Bai, M., Yu, Y., et al. (2021) Continuous Renal Re-placement Therapy without Anticoagulation in Critically Ill Patients at High Risk of Bleeding: A Systematic Review and Meta-Analysis. Seminars in Dialysis, 34, 196-208.
https://doi.org/10.1111/sdi.12946
|
[17]
|
Choi, J.-Y., Kang, Y.-J., Jang, H.-M., et al. (2015) Nafamostat Mesilate as an Anticoagulant during Continuous Renal Replacement Therapy in Patients with High Bleeding Risk: A Randomized Clinical Trial. Medicine, 94, e2392.
https://doi.org/10.1097/MD.0000000000002392
|
[18]
|
Li, L., Bai, M., Zhang, W., et al. (2022) Regional Citrate An-ticoagulation versus Low Molecular Weight Heparin for CRRT in Hyperlactatemia Patients: A Retrospective Case-Control Study. The International Journal of Artificial Organs, 45, 343-350. https://doi.org/10.1177/03913988211003586
|
[19]
|
张琪, 丁峰. 连续性肾脏替代治疗中局部枸橼酸抗凝的临床监测及风险评估[J]. 华西医学, 2022, 37(7): 1088-1093.
|
[20]
|
北村伸哉, 张凌. 甲磺酸萘莫司他在连续性肾脏替代治疗中的抗凝应用[J]. 华西医学, 2018, 33(7): 801-805.
|
[21]
|
Tsujimoto, H., Tsujimoto, Y., Nakata, Y., et al. (2020) Pharmacological Interventions for Preventing Clotting of Extracorporeal Circuits during Continuous Renal Replacement Therapy. Cochrane Database of Systematic Reviews, 3, Article ID: CD12467. https://doi.org/10.1002/14651858.CD012467.pub2
|
[22]
|
Baek, N.N., Jang, H.R., Huh, W., et al. (2012) The Role of Nafamostat Mesylate in Continuous Renal Replacement Therapy among Patients at High Risk of Bleeding. Renal Failure, 34, 279-285.
https://doi.org/10.3109/0886022X.2011.647293
|
[23]
|
Makino, S., Egi, M., Kita, H., et al. (2016) Comparison of Nafamostat Mesilate and Unfractionated Heparin as Anticoagulants during Continuous Renal Replacement Therapy. The International Journal of Artificial Organs, 39, 16-21.
https://doi.org/10.5301/ijao.5000465
|
[24]
|
Hwang, S.D., Hyun, Y.K., Moon, S.J., Lee, S.C. and Yoon, S.Y. (2013) Nafamostat Mesilate for Anticoagulation in Continuous Renal Replacement Therapy. The International Journal of Artifi-cial Organs, 36, 208-216.
https://doi.org/10.5301/ijao.5000191
|
[25]
|
Iwama, H., Watanabe, K. and Obara, S. (2003) In Vitro Relationship between the Blood Nafamostat Concentration and Activated Coagulation Time. Canadian Journal of Anesthesia, 50, 621-622. https://doi.org/10.1007/BF03018658
|
[26]
|
Yamada, S. and Asakura, H. (2011) Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm. International Journal of Molecular Sciences, 23, Article No. 1296.
https://doi.org/10.3390/ijms23031296
|
[27]
|
Miyatake, Y., Makino, S., Kubota, K., Egi, M. and Mizobuchi, S. (2017) Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy Using Nafamostat Mesilate: A Retrospective Pilot Observational Study. Kobe Journal of Medical Sciences, 63, E30-E36.
|
[28]
|
Shioya, N., Inoue, N., Sato, H., et al. (2022) Cardiopulmonary Arrest Caused by Nafamostat Mesylate during Hemodialysis. Clinical Case Reports, 10, e6140. https://doi.org/10.1002/ccr3.6140
|
[29]
|
Aiso, M., Takikawa, H., Tsuji, K., et al. (2019) Analysis of 307 Cases with Drug-Induced Liver Injury between 2010 and 2018 in Japan. Hepatology Research, 49, 105-110. https://doi.org/10.1111/hepr.13288
|
[30]
|
Santos, A.F., Alpan, O. and Hoffmann, H.-J. (2021) Basophil Activation Test: Mechanisms and Considerations for Use in Clinical Trials and Clinical Practice. Allergy, 76, 2420-2432. https://doi.org/10.1111/all.14747
|
[31]
|
Kim, J.-H., Park, J.Y., Jang, S.H., et al. (2021) Fatal Anaphylaxis due to Nafamostat Mesylate during Hemodialysis. Allergy, Asthma & Immunology Research, 13, 517-519. https://doi.org/10.4168/aair.2021.13.3.517
|